MSSTF is projected to have lab-grade/Pharma-Grade psilocybin compounds available this fall. All these other psilocybin/psychedelic pennies are gonna need compounds from someone. Why not MSSTF?
MSSTF will hopefully start generating revenues later in CY21 - and is 2-3 years AHEAD of other companies - that are still going thru clinical trials where actual revenues are still 2-3 years away.
Mindset Pharma (OTCQB:MSSTF) has selected its lead clinical candidate, MSP-1014, a differentiated psilocybin-based compound to move forward into current good manufacturing practice ((cGMP)) compliant manufacturing and investigational new drug (IND)-enabling studies. MSP-1014 has the potential to be a safer, more efficacious analog to psilocybin, with reduced potential side effects, the company said. The company anticipates MSP-1014 to have the potential to treat mood disorders, including major depressive disorder, substance misuse disorders and end-of-life angst associated with terminal illnesses, including cancer. MSP-1014 demonstrates superior preclinical characteristics in head-to-head comparison with psilocybin and its active metabolite psilocin, including increased safety and efficacy.